FDA approves imlunestrant plus abemaciclib for ESR1-mutated breast cancer, doubling progression-free survival in Phase 3 trials.

Phase 2 RIO trial shows 3BNC117-LS and 10-1074-LS delay HIV viral rebound after treatment interruption, but resistance patterns raise...

Certara launches External Data Accelerator to catch vendor data conformance issues before submission, addressing 70% of clinical study data...

Boehringer Ingelheim's PED Essentials teaches patient organizations to collect and structure patient experience data for regulatory submissions and advocacy.

New analysis suggests nonmelanoma skin cancer cases are 42% higher than official counts, with annual patient numbers reaching 4.7...

Kamada confirms KedRAB supply meets surge in rabies inquiries. CDC reports 17% increase in rabies-related cases through summer 2026.

MIRA Pharmaceuticals initiates Phase 2a study of Ketamir-2 for chemotherapy-induced peripheral neuropathy, targeting an undertreated condition affecting over ha

PEDMARK hearing protection met its primary endpoint in a Phase 2 study, showing significant ototoxicity reduction without compromising cisplatin's...

Mayo Test Drive completed at 97.5% across MCI, mild, and moderate dementia patients, here's what that means for Alzheimer's...

Medpace expands Phase I Unit with on-site imaging and specialized assessments to reduce participant dropout and keep trial endpoints...